Key Highlights

  • Loss per share was USD 0.67, matching an estimate of a USD 0.67 loss.
  • Net loss was USD 29.66 million, against USD 23.58 million a year earlier.
  • Research and development expenses were USD 25.49 million, against USD 22.09 million.
  • Cash and marketable securities were USD 386.6 million at September 30.

Avalyn Pharma (NASDAQ:AVLN) reported a third quarter 2026 loss per share of USD 0.67, matching an estimate of a USD 0.67 loss. Net loss was USD 29.66 million, compared with USD 23.58 million in the third quarter of 2025.

The loss from operations was USD 33.09 million, compared with USD 25.32 million. Other income was USD 3.44 million, compared with USD 1.74 million.

Operating Expenses

Research and development expenses were USD 25.49 million, compared with USD 22.09 million. General and administrative expenses were USD 7.60 million, compared with USD 3.23 million. Total operating expenses were USD 33.09 million, compared with USD 25.32 million.

The filing reports total share-based compensation of USD 3.10 million, compared with USD 725 thousand, including USD 1.89 million within general and administrative expenses and USD 1.21 million within Research and Development expenses.

Nine-Month Results

For the nine months ended September 30, 2026, net loss was USD 85.46 million, compared with USD 61.28 million. Total operating expenses were USD 92.29 million, against USD 65.82 million. Research and development expenses for the nine months were USD 73.11 million, against USD 55.29 million, and general and administrative expenses were USD 19.18 million, against USD 10.53 million.

Other income for the nine months was USD 6.83 million, compared with USD 4.54 million, and total share-based compensation was USD 7.08 million, compared with USD 2.40 million.

Cash Runway and Pipeline

As of September 30, 2026, the company had cash, cash equivalents and marketable securities of USD 386.6 million. Based on its current operating plans, the company believes these resources are sufficient to fund operating expenses and capital expenditures into 2029.

The filing describes the company's lead product candidate, AP01 inhaled pirfenidone, as an optimized inhaled formulation of pirfenidone that is currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis.

In April 2017, the company entered into a license agreement with PARI Pharma GmbH. The filing states that the company agreed to make payments upon the achievement of certain developmental and regulatory milestones relating to its drug product, including initiation of Phase 2 and Phase 3 clinical trials, acceptance for filing by the FDA or the European Medicines Agency, and approval by either agency.

The filing describes the company's initial public offering, in which it sold an aggregate of 19,166,667 shares of common stock at a public offering price of USD 18.00 per share, including 2,500,000 shares sold to the underwriters on the full exercise of their option, resulting in aggregate net proceeds of approximately USD 316.6 million. Immediately before the closing of the offering, the outstanding redeemable convertible preferred stock automatically converted into 23,918,194 shares of common stock, and no shares of redeemable convertible preferred stock remained outstanding afterward.

Avalyn Pharma Q3 2026 Earnings: Key Takeaways

Avalyn Pharma reported a third quarter 2026 loss per share of USD 0.67 and a net loss of USD 29.66 million. Research and development expenses were USD 25.49 million, and cash, cash equivalents and marketable securities were USD 386.6 million.